DE69217308D1 - Dihydropyridine zur Anwendung in der Antitumor-Therapie - Google Patents

Dihydropyridine zur Anwendung in der Antitumor-Therapie

Info

Publication number
DE69217308D1
DE69217308D1 DE69217308T DE69217308T DE69217308D1 DE 69217308 D1 DE69217308 D1 DE 69217308D1 DE 69217308 T DE69217308 T DE 69217308T DE 69217308 T DE69217308 T DE 69217308T DE 69217308 D1 DE69217308 D1 DE 69217308D1
Authority
DE
Germany
Prior art keywords
chem
alkoxy
group
alkyl optionally
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69217308T
Other languages
English (en)
Other versions
DE69217308T2 (de
Inventor
Paolo Cozzi
Maria Menichincheri
Laura Capolongo
Nicola Mongelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Pharmacia and Upjohn SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn SpA filed Critical Pharmacia and Upjohn SpA
Publication of DE69217308D1 publication Critical patent/DE69217308D1/de
Application granted granted Critical
Publication of DE69217308T2 publication Critical patent/DE69217308T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
DE69217308T 1991-09-19 1992-09-18 Dihydropyridine zur Anwendung in der Antitumor-Therapie Expired - Fee Related DE69217308T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919119983A GB9119983D0 (en) 1991-09-19 1991-09-19 Dihydropyridine derivatives useful in antitumor therapy

Publications (2)

Publication Number Publication Date
DE69217308D1 true DE69217308D1 (de) 1997-03-20
DE69217308T2 DE69217308T2 (de) 1997-05-28

Family

ID=10701636

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69217308T Expired - Fee Related DE69217308T2 (de) 1991-09-19 1992-09-18 Dihydropyridine zur Anwendung in der Antitumor-Therapie

Country Status (21)

Country Link
US (1) US5362729A (de)
EP (1) EP0533504B1 (de)
JP (1) JPH05213935A (de)
KR (1) KR930006002A (de)
AT (1) ATE148698T1 (de)
AU (1) AU651001B2 (de)
CA (1) CA2078606A1 (de)
DE (1) DE69217308T2 (de)
DK (1) DK0533504T3 (de)
ES (1) ES2099800T3 (de)
FI (1) FI98215C (de)
GB (1) GB9119983D0 (de)
GR (1) GR3022988T3 (de)
HU (1) HUT61994A (de)
IL (1) IL103019A (de)
MX (1) MX9205207A (de)
MY (1) MY129935A (de)
NZ (1) NZ244280A (de)
RU (1) RU2086548C1 (de)
TW (1) TW283147B (de)
ZA (1) ZA927115B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508410A (en) * 1993-11-30 1996-04-16 Reilly Industries, Inc. Process for preparing 2-halo-5-substituted pyridines
US5668151A (en) * 1995-06-07 1997-09-16 Bristol-Myers Squibb Company Dihydropyridine NPY antagonists: piperidine derivatives
US5554621A (en) * 1995-06-07 1996-09-10 Bristol-Myers Squibb Company Dihydropyridine NPY antagonists: nitrogen heterocyclic derivatives
GB9515445D0 (en) * 1995-07-27 1995-09-27 Pharmacia Spa Dihydropyridine and pyridine derivatives and process for their preparation
GB2310136A (en) * 1996-02-16 1997-08-20 Pharmacia Spa Dihydropyridine derivatives as aromatase inhibitors
US5889016A (en) * 1997-06-26 1999-03-30 Bristol-Myers Squibb Company Dihydropyrimidone derivatives as NPY antagonists
ES2151850B1 (es) * 1998-10-26 2001-08-16 Esteve Quimica Sa Intermedio para la sintesis de amlodipino para su obtencion y utilizacion correspondiente.
AU764627B2 (en) 1999-06-21 2003-08-28 Bristol-Myers Squibb Company Dihydropyrazine derivatives as NPY antagonists
US6376514B1 (en) 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
US8906392B2 (en) * 2005-12-16 2014-12-09 University Of Kansas Nanocluster compositions and methods
WO2010009146A1 (en) * 2008-07-15 2010-01-21 University Of Kansas Nanoclusters for delivery of poorly water soluble drug nanoparticles
US10258498B2 (en) 2011-11-24 2019-04-16 Richter Gedeon Nyrt. 1,4-dihydropyridine derivatives with Hsp modulating activity
CN105175326B (zh) * 2015-08-19 2018-02-27 四川国康药业有限公司 5‑甲基‑2(1h)吡啶酮衍生物及其制备方法和用途
KR102528669B1 (ko) * 2016-06-10 2023-05-04 엘지전자 주식회사 식기 세척기

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670827C3 (de) * 1967-03-20 1974-10-24 Bayer Ag, 5090 Leverkusen 4-(2'-Nitrophenyl)-2,6-dimethyl-3,5-dicarbmethoxy-1,4-dihydropyridin
DE2508181A1 (de) * 1975-02-26 1976-09-09 Bayer Ag 1,4-dihydropyridincarbonsaeurearal- kylester, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
SU725406A1 (ru) * 1978-08-08 1981-07-30 Ордена Трудового Красного Знамениинститут Органического Синтеза Ah Латвий-Ской Ccp Эфиры диметил дигидропиридин диКАРбОНОВОй КиСлОТы,ОблАдАющиЕ АНТи-МЕТАСТАТичЕСКОй АКТиВНОСТью
JPS58159490A (ja) * 1982-02-23 1983-09-21 Nikken Kagaku Kk １，４−ジヒドロピリジン化合物
DE3478685D1 (en) * 1983-03-04 1989-07-20 Nikken Chemicals Co Ltd 1,4-dihydropyridine compound
US4906646A (en) * 1983-03-31 1990-03-06 Board Of Governors Of Wayne State University Method and composition for the treatment of tumors by administering a platinum coordination compound and a calcium channel blocker compound of the dihydropyridine class
US4690935A (en) * 1983-03-31 1987-09-01 Wayne State University Inhibition of tumor growth and metastasis with calcium channel blocker compounds
DE3326384A1 (de) * 1983-07-22 1985-01-31 Bayer Ag, 5090 Leverkusen 1,4-dihydropyridine, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
SU1125957A1 (ru) * 1983-10-20 1986-03-23 Ордена Трудового Красного Знамени Институт Органического Синтеза Ан Латвсср 4-(3-Метилпиразолил-4)-2,6-диметил-3,5-диэтоксикарбонил-1,4-дигидропиридин ,об ладающий гепатопротекторной активностью
IT1201454B (it) * 1985-08-19 1989-02-02 Boehringer Biochemia Srl 1,4-diidropiridine-2-sostituite
DE3601196A1 (de) * 1986-01-17 1987-07-23 Merck Patent Gmbh 1,4-dihydropyridine
IT1204459B (it) * 1986-02-20 1989-03-01 Glaxo Spa Derivati eterociclici
JPS63135381A (ja) * 1986-11-26 1988-06-07 Kyorin Pharmaceut Co Ltd 多剤耐性癌細胞に対する感受性増強剤及びその製造方法
DE3711991A1 (de) * 1987-04-09 1988-10-20 Bayer Ag Dihydropyridinamide, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
JPH02167262A (ja) * 1988-06-05 1990-06-27 Taisho Pharmaceut Co Ltd １，４―ジヒドロピリジン誘導体
DE68909873T2 (de) * 1988-07-28 1994-02-10 Nikken Chemicals Co Ltd 1,4-Dihydropyridin-Derivate.
JP2640245B2 (ja) * 1988-07-28 1997-08-13 日研化学株式会社 １，４−ジヒドロピリジン誘導体
IL92646A0 (en) * 1988-12-15 1990-08-31 Erba Carlo Spa Imidazolyl and pyridyl derivatives of phenyl substituted 1,4-dihydropyridines,their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
GR3022988T3 (en) 1997-07-30
MX9205207A (es) 1993-03-01
ATE148698T1 (de) 1997-02-15
ES2099800T3 (es) 1997-06-01
IL103019A0 (en) 1993-02-21
MY129935A (en) 2007-05-31
FI98215C (fi) 1997-05-12
EP0533504B1 (de) 1997-02-05
HU9202934D0 (en) 1992-11-30
IL103019A (en) 1996-10-31
FI98215B (fi) 1997-01-31
RU2086548C1 (ru) 1997-08-10
DE69217308T2 (de) 1997-05-28
CA2078606A1 (en) 1993-03-20
AU2359392A (en) 1993-03-25
HUT61994A (en) 1993-03-29
US5362729A (en) 1994-11-08
JPH05213935A (ja) 1993-08-24
ZA927115B (en) 1993-03-22
FI924110A0 (fi) 1992-09-14
DK0533504T3 (da) 1997-04-07
FI924110A (fi) 1993-03-20
EP0533504A1 (de) 1993-03-24
NZ244280A (en) 1995-02-24
GB9119983D0 (en) 1991-11-06
AU651001B2 (en) 1994-07-07
TW283147B (de) 1996-08-11
KR930006002A (ko) 1993-04-20

Similar Documents

Publication Publication Date Title
DE69217308D1 (de) Dihydropyridine zur Anwendung in der Antitumor-Therapie
ATE211735T1 (de) 1-phenyl-pyrazolderivate und ihr verwendung als schädlingsbekämpfungsmittel
DE69919897D1 (en) 4-oxo-1,4-dihydro-3-chinolincarboxamide als antivirale mittel
ATE119774T1 (de) Imidazopyridinderivate und ihre verwendung.
ES2167371T3 (es) Derivados de 1h-3-aril-pirrolidin-2,4-diona espirociclicos substituidos.
BG102792A (en) Substituted derivatives of 4-hydroxyphenylalkane acids having antagonists activity to ppar-gama.
BG104287A (en) Halogensubstituted tetracyclic derivatives of tetrahydrofuran
FR2619111B1 (fr) Derives de (piperidinyl-4)methyl-2 tetrahydro-1,2,3,4 9h-pyrido (3,4-b) indole, leur preparation et leur application en therapeutique
DE122011100040I2 (de) Zusammensetzung, verfahren und instrument zur potenzierung der antitumoraktivitat und zur behandlungvon tumoren.
CA2207784A1 (en) Certain pyrrolopyridine derivatives; novel crf1 specific ligands
ATE263771T1 (de) Totalsynthese von acylfulvenen mit antitumorwirkung
IL119828A0 (en) Substituted triazine derivatives their preparation and use
DE3575140D1 (de) Dreizyklische oxindole als antientzuendungsmittel.
MY131762A (en) Pharmaceutical compounds
DE69301639T2 (de) Tetrahydronaphtalenderivate, ihre Herstellung und ihre therapeutische Verwendung
DK0516486T3 (da) Azetidinonderivater egnede til fremstilling af carbapenemantibiotika
CA2272136A1 (en) Pyrazole derivatives having crf antagonist activity

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee